Chenguang Shen

Featured in: Favicon

nature.com Favicon

frontiersin.org Favicon

jamanetwork.com Favicon

science.org Favicon

jacionline.org Favicon

journalofinfection.com Favicon

onlinelibrary.wiley.com

Articles

Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19

May 31, 2023 | mdpi.com | Chenguang Shen |Jie Peng |Zuning Ren

Abstract:The monoclonal antibody (mAb)-based treatment is a highly valued therapy against COVID-19, especially for individuals who may not have strong immune responses to the vaccine. However, with the arrival of the Omicron variant and its evolving subvariants, along with the occurrence of remarkable resistance of these SARS-CoV-2 variants to the neutralizing antibodies, mAbs are facing tough challenges.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →